Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Bemarituzumab by Amgen for Squamous Non-Small Cell Lung Cancer: Likelihood of Approval
Bemarituzumab is under clinical development by Amgen and currently in Phase I for Squamous Non-Small Cell Lung Cancer. According to...
Talimogene laherparepvec by Amgen for Kaposi Sarcoma: Likelihood of Approval
Talimogene laherparepvec is under clinical development by Amgen and currently in Phase II for Kaposi Sarcoma. According to GlobalData, Phase...
Bemarituzumab by Amgen for Lung Adenocarcinoma: Likelihood of Approval
Bemarituzumab is under clinical development by Amgen and currently in Phase II for Lung Adenocarcinoma. According to GlobalData, Phase II...
Carfilzomib by Amgen for Multiple Myeloma (Kahler Disease): Likelihood of Approval
Carfilzomib is under clinical development by Amgen and currently in Phase III for Multiple Myeloma (Kahler Disease). According to GlobalData,...
Romosozumab by Amgen for Osteogenesis Imperfecta: Likelihood of Approval
Romosozumab is under clinical development by Amgen and currently in Phase I for Osteogenesis Imperfecta. According to GlobalData, Phase I...
Bemarituzumab by Amgen for Peritoneal Cancer: Likelihood of Approval
Bemarituzumab is under clinical development by Amgen and currently in Phase II for Peritoneal Cancer. According to GlobalData, Phase II...
Blinatumomab by Amgen for Lymphoblastic Lymphoma: Likelihood of Approval
Blinatumomab is under clinical development by Amgen and currently in Phase III for Lymphoblastic Lymphoma. According to GlobalData, Phase III...
Bemarituzumab by Amgen for Fallopian Tube Cancer: Likelihood of Approval
Bemarituzumab is under clinical development by Amgen and currently in Phase II for Fallopian Tube Cancer. According to GlobalData, Phase...
Talimogene laherparepvec by Amgen for Metastatic Hepatocellular Carcinoma (HCC): Likelihood of Approval
Talimogene laherparepvec is under clinical development by Amgen and currently in Phase II for Metastatic Hepatocellular Carcinoma (HCC). According to...
Talimogene laherparepvec by Amgen for Non-Small Cell Lung Cancer: Likelihood of Approval
Talimogene laherparepvec is under clinical development by Amgen and currently in Phase II for Non-Small Cell Lung Cancer. According to...
Talimogene laherparepvec by Amgen for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
Talimogene laherparepvec is under clinical development by Amgen and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to...
Zeluvalimab by Amgen for Ovarian Cancer: Likelihood of Approval
Zeluvalimab is under clinical development by Amgen and currently in Phase I for Ovarian Cancer. According to GlobalData, Phase I...
Zeluvalimab by Amgen for Small-Cell Lung Cancer: Likelihood of Approval
Zeluvalimab is under clinical development by Amgen and currently in Phase I for Small-Cell Lung Cancer. According to GlobalData, Phase...
Denosumab by Amgen for Male Infertility: Likelihood of Approval
Denosumab is under clinical development by Amgen and currently in Phase II for Male Infertility. According to GlobalData, Phase II...
Tezepelumab by Amgen for Chronic Urticaria Or Hives: Likelihood of Approval
Tezepelumab is under clinical development by Amgen and currently in Phase II for Chronic Urticaria Or Hives. According to GlobalData,...
Rozibafusp alfa by Amgen for Systemic Lupus Erythematosus: Likelihood of Approval
Rozibafusp alfa is under clinical development by Amgen and currently in Phase II for Systemic Lupus Erythematosus. According to GlobalData,...
Erenumab by Amgen for Pain: Likelihood of Approval
Erenumab is under clinical development by Amgen and currently in Phase II for Pain. According to GlobalData, Phase II drugs...
Apremilast by Amgen for Bullous Pemphigoid: Likelihood of Approval
Apremilast is under clinical development by Amgen and currently in Phase II for Bullous Pemphigoid. According to GlobalData, Phase II...
Zeluvalimab by Amgen for Metastatic Adenocarcinoma of The Pancreas: Likelihood of Approval
Zeluvalimab is under clinical development by Amgen and currently in Phase I for Metastatic Adenocarcinoma of The Pancreas. According to...
Zeluvalimab by Amgen for Malignant Mesothelioma: Likelihood of Approval
Zeluvalimab is under clinical development by Amgen and currently in Phase I for Malignant Mesothelioma. According to GlobalData, Phase I...